Lundbeck Completes Patient Randomization in Phase 3 Trial for Potential MSA Treatment

Lundbeck Completes Patient Randomization in Phase 3 Trial for Potential MSA Treatment

By, Admin 12 March 2026

A major milestone has been reached in the search for treatments for Multiple System Atrophy (MSA).

H. Lundbeck A/S, a biopharmaceutical company focused on brain health, has announced the completion of patient randomization in its global Phase 3 MASCOT trial evaluating the investigational therapy amlenetug.

The achievement marks an important step toward developing a potential treatment for a rare and rapidly progressing neurological disorder that currently has no approved disease-modifying therapies.

A Key Milestone for a Rare Neurodegenerative Disease

The MASCOT trial is a global Phase 3 clinical study designed to evaluate whether amlenetug can slow disease progression in patients with MSA.

Patient randomization finished earlier than expected. This reflects strong participation from the global MSA community and collaboration across research centers worldwide.

The multicenter trial is currently running across:

  • North America
  • Europe
  • Asia
  • Australia

Researchers will continue monitoring patients as they progress through the study’s treatment phases.

Expert Perspective on the Trial Progress

According to the trial’s lead investigator, completing enrollment is a significant moment for the field.

Günter Höglinger, Professor and lead investigator of the MASCOT trial, emphasized the importance of advancing therapies for patients with limited options.

He noted that developing treatments for MSA addresses a critical unmet need for individuals living with the condition.

Why Amlenetug Could Be a First-in-Class Therapy?

Amlenetug is designed to target alpha-synuclein, a protein believed to play a key role in the development of MSA.

The investigational therapy works by:

  • Binding to extracellular α-synuclein proteins
  • Preventing their spread between brain cells
  • Blocking the aggregation process that contributes to neurodegeneration

By addressing a core disease mechanism, the therapy could potentially become a first-in-class treatment for MSA.

The drug is being developed by H. Lundbeck A/S through a joint research and licensing agreement with Genmab A/S.

Regulatory Support for the Investigational Therapy

Amlenetug has already received several regulatory designations designed to accelerate development:

  • Orphan Drug Designation in the United States, European Union, and Japan
  • Fast Track designation from the U.S. FDA
  • SAKIGAKE designation in Japan

These recognitions highlight the urgent need for therapies targeting rare diseases like MSA.

However, the drug remains investigational and has not yet been approved by any regulatory authority.

Understanding Multiple System Atrophy

Multiple System Atrophy is a rare and fatal neurodegenerative disorder characterized by progressive damage to nerve cells in the brain.

The disease is associated with the abnormal buildup of alpha-synuclein protein, which disrupts brain regions responsible for:

  • Movement
  • Balance
  • Autonomic body functions

MSA symptoms typically begin between 55 and 60 years of age.

Common symptoms include:

  • Muscle control problems similar to Parkinson’s disease
  • Frequent falls
  • Urinary incontinence
  • Slurred or unintelligible speech

Within just a few years of onset, many patients experience severe disability and loss of independence.

On average, life expectancy after symptom onset is about 8.6 years, with death often resulting from respiratory complications.

Currently, there is no cure and no approved therapy that slows disease progression.

Inside the MASCOT Phase 3 Trial

The MASCOT trial is the first Phase 3 study evaluating amlenetug in MSA patients. The study includes two phases:

1. Double-Blind Treatment Phase

Participants are randomly assigned to receive:

  • High-dose amlenetug
  • Low-dose amlenetug
  • Placebo

Treatment is administered every four weeks via intravenous infusion for 72 weeks.

2. Open-Label Extension Phase

After the initial study period:

  • All participants are offered treatment with amlenetug
  • Researchers continue evaluating long-term safety and efficacy

The trial aims to assess:

  • Efficacy in slowing disease progression
  • Safety and tolerability of the therapy
  • Overall patient outcomes

What Comes Next?

With patient randomization now complete, the trial will continue with participants progressing through the treatment period and long-term follow-up.

For patients living with MSA, the outcome of the MASCOT study could represent a critical step toward the first disease-modifying therapy for this devastating disorder.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!